A Study to Evaluate Scales for Repetitive and Restricted Behaviors in Children, Adolescents, and Adults With Autism Spectrum Disorder (ASD)
Status: | Recruiting |
---|---|
Conditions: | Neurology, Psychiatric, Psychiatric, Autism |
Therapuetic Areas: | Neurology, Psychiatry / Psychology |
Healthy: | No |
Age Range: | 5 - 45 |
Updated: | 3/22/2019 |
Start Date: | August 13, 2018 |
End Date: | August 30, 2019 |
Contact: | Reference Study ID Number: BP40331 www.roche.com/about_roche/roche_worldwide.htm |
Email: | global-roche-genentech-trials@gene.com |
Phone: | 888-662-6728 (U.S. and Canada) |
Study to Evaluate and Explore Scales for Repetitive and Restricted Behaviors and Digital Biomarkers in Children, Adolescents, and Adults With Autism Spectrum Disorder (ASD)
This is a non-drug study seeking to characterize different scales to measure repetitive and
restrictive behaviors in different ASD sub-populations over time. This study will also
explore the use of digital biomarkers.
restrictive behaviors in different ASD sub-populations over time. This study will also
explore the use of digital biomarkers.
Inclusion Criteria for All Participants
- Males and females
- Availability of a parent or other reliable caregiver. The same person must agree to
accompany the participant to all clinic visits and provide information about the
participant's behavior and symptoms
Inclusion Criteria for Participants with Autism Spectrum Disorders (ASD)(Diagnostic
evaluations will be completed at study site by research staff and supervised by a licensed
psychologist)
- Age: 5-45 years
- Diagnosis of ASD based on the Diagnostic and Statistical Manual of Mental Disorders
(DSM-5), and the Autism Diagnostic Observation Schedule (ADOS-2).
- Children's Yale-Brown Obsessive Compulsive Scale modified for ASD (CY-BOCS-ASD) total
score of at least 12
- Clinical Global Impression-Severity (CGI-S) scale of at least 4 about participant's
current autism severity
- Intelligence quotient (IQ) score of 50 or above as assessed by the Abbreviated
Intelligence Quotient (ABIQ) SB5 scale
- All medications and treatments are expected to be stable for the duration of the study
Inclusion Criteria for Healthy Volunteers
-Children ages 5-12 years
Exclusion Criteria for All Participants
- Participation in an in investigational drug or device study within 4 weeks or 5 times
the half-life of the investigational molecule prior to screening, and participant is
not expected to enroll in any other trial during the study
- Co-occurring disease, condition, or treatment that might interfere with the conduct of
the study or pose an unacceptable risk to the participant
- Unstable or uncontrolled clinically significant psychiatric and/or neurological
disorder that may interfere with study objectives
Exclusion Criteria for Participants with ASD -Known "syndromic" ASD (e.g. Fragile X
syndrome, Angelman syndrome, Prader-Willi, Rett's syndrome, tuberous sclerosis, Dup15q
syndrome) History of alcohol misuse and/or illicit drug use during the last 12 months of
the study
Exclusion Criteria for Healthy Volunteers
-Healthy children with a brother or sister with ASD (first-degree sibling)
We found this trial at
18
sites
Albert Einstein College of Medicine The Albert Einstein College of Medicine of Yeshiva University is...
Click here to add this to my saved trials
Children's Hospital of Philadelphia Since its start in 1855 as the nation's first hospital devoted...
Click here to add this to my saved trials
Stanford University School of Medicine Vast in both its physical scale and its impact on...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
5200 Belfort Road
Jacksonville, Florida 32256
Jacksonville, Florida 32256
Click here to add this to my saved trials
10833 Le Conte Ave
Los Angeles, California 90095
Los Angeles, California 90095
(310) 825-4321
David Geffen School of Medicine, UCLA In 2002 Mr. David Geffen announced a $200 million...
Click here to add this to my saved trials
720 Southeast Washington Avenue
Minneapolis, Minnesota 55414
Minneapolis, Minnesota 55414
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials